Today, the VP, Chief Medical Officer of GTx (NASDAQ: GTXI), Diane Young, bought shares of GTXI for $30.12K.
Following Diane Young’s last GTXI Buy transaction on February 28, 2017, the stock climbed by 10.2%. This recent transaction increases Diane Young’s holding in the company by 4.67% to a total of $683.1K.
See today’s analyst top recommended stocks >>
Currently, GTx has an average volume of 39.64K. The Company has a Price to Book ratio of 13.5365.
Starting in November 2017, GTXI received 6 Buy ratings in a row. Five different firms, including Citigroup and Jefferies, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $316K worth of GTXI shares and purchased $113.9K worth of GTXI shares. The insider sentiment on GTx has been negative according to 23 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions.
